Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374917 · ClinicalTrials.gov registry record · Phase 1
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
A Phase 1 study of Parkinsons Disease (PD), sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 12
- Study locations
NCT03374917: Completed Phase 1 study of Parkinsons Disease (PD), sponsored by AbbVie.
NCT03374917 is a Phase 1 study of Parkinsons Disease (PD) that has completed, run by AbbVie. The registered enrollment target is 20 participants, below the 118-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (83% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03374917, a Phase 1 study of Parkinsons Disease (PD), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
Primary Outcome
Local tolerability (infusion site evaluation) was assessed using the Infusion Site Assessment 2-part rating scale.
Conditions Studied
Interventions
- DRUG ABBV-951
Study Locations (12)
California
- Loma Linda University /ID# 165592 - Loma Linda
- Univ CA, Irvine Med Ctr /ID# 165594 - Orange
Kentucky
- University of Kentucky Chandler Medical Center /ID# 164407 - Lexington
- University of Louisville /ID# 164997 - Louisville
Ohio
- University of Cincinnati /ID# 165142 - Cincinnati
- Cleveland Clinic Foundation /ID# 164413 - Cleveland
Arizona
- Banner Sun Health Res Inst /ID# 165840 - Sun City
Florida
- Compass Research /ID# 167329 - Orlando
Kansas
- Univ Kansas Med Ctr /ID# 166280 - Kansas City
Missouri
- Washington University-School of Medicine /ID# 164412 - St Louis
New York
- NYU Langone Medical Center /ID# 164924 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-03-04 |
| Phase | Phase 1 |
What the finished NCT03374917 record still lists
NCT03374917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 118-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which ABBV-951 is the first listed.
NCT03374917 lists 12 locations in 9 states (California, Kentucky, Ohio).
Frequently Asked Questions
What is clinical trial NCT03374917 about?
NCT03374917 is a clinical study titled "A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
What is the current status of trial NCT03374917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-04-18. Estimated completion is 2019-03-04.
What conditions does trial NCT03374917 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT03374917?
The interventions under investigation include: ABBV-951 (DRUG).
Who is sponsoring clinical trial NCT03374917?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374917 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03374917's enrollment target sits among peer trials
20 18th of 19 higher than 2 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI